Literature DB >> 18042562

Insurers and 'targeted biologics' for cancer: a conversation with Lee N. Newcomer. Interview by Barbara J. Culliton.

Lee N Newcomer.   

Abstract

New drugs for cancer, targeted at the specific genetic profile of various tumors, are revolutionizing cancer therapy, but at a very high cost. Most carry a price tag of $50,000 or more per patient per year. Lee Newcomer examines the medical and policy issues from his perspective at United Healthcare and from his experience as an oncologist. In this interview, Newcomer suggests that all patients receiving the targeted biologics be required to participate in a clinical trial or an insurance company registry so that data can be collected to assure that the right drugs are prescribed for the right patients.

Entities:  

Mesh：

Year:  2007        PMID： 18042562     DOI： 10.1377/hlthaff.27.1.w41

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN： 0278-2715            Impact factor:   6.301


  7 in total

1.  Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.

Authors:  Julia R Trosman; Stephanie L Van Bebber; Kathryn A Phillips
Journal:  J Oncol Pract       Date:  2010-09       Impact factor: 3.840

2.  Closing the evidence gap in the use of emerging testing technologies in clinical practice.

Authors:  Kathryn A Phillips
Journal:  JAMA       Date:  2008-12-03       Impact factor: 56.272

Review 3.  Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value.

Authors:  Kathryn A Phillips; Su-Ying Liang; Stephanie Van Bebber
Journal:  Curr Opin Mol Ther       Date:  2008-06

4.  Genomic testing and therapies for breast cancer in clinical practice.

Authors:  Jennifer S Haas; Kathryn A Phillips; Su-Ying Liang; Michael J Hassett; Carol Keohane; Elena B Elkin; Joanne Armstrong; Michele Toscano
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

5.  Capacity building for assessing new technologies: approaches to examining personalized medicine in practice.

Authors:  Stephanie L Van Bebber; Julia R Trosman; Su-Ying Liang; Grace Wang; Deborah A Marshall; Sara Knight; Kathryn A Phillips
Journal:  Per Med       Date:  2010-07       Impact factor: 2.512

6.  First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer.

Authors:  Ya-Chen Tina Shih; Ying Xu; Wenli Dong; Fabrice Smieliauskas; Sharon Giordano; Yu Shen
Journal:  Breast Cancer Res Treat       Date:  2014-02-21       Impact factor: 4.872

7.  Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.

Authors:  Kathryn A Phillips; Deborah A Marshall; Jennifer S Haas; Elena B Elkin; Su-Ying Liang; Michael J Hassett; Ilia Ferrusi; Jane E Brock; Stephanie L Van Bebber
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.